替吉奥维持治疗晚期转移性乳腺癌临床观察  

Clinical observation of S-1 as maintenance treatment for advanced breast cancer

作　　者：于韦韦[1] 张捷[1] 时淑珍[1] 

机构地区：[1]大连市第三人民医院肿瘤一病房,116033

出　　处：《中国现代药物应用》2014年第2期10-11,共2页Chinese Journal of Modern Drug Application

摘　　要：目的 观察替吉奥维持治疗晚期转移性乳腺癌的临床疗效及毒副反应.方法 回顾性分析医院2011年1月~2013年4月转移性乳腺癌患者22例.采用替吉奥单药口服,40~60 mg（＆lt;1.25 m2 40 mg;1.25~1.5 m2 50 mg;＆gt;1.5 m2 60 mg）,早晚饭后口服,连服14 d,21 d为一周期,直至PD或不良反应无法耐受则终止治疗.结果 CR 0例,PR 7例,SD 8例,PD 7例,总有效率（RR）31.8%,疾病控制率（DCR）68.2%,中位无进展生存期（PFS）6.8个月.常见不良反应为Ⅰ~Ⅱ°骨髓抑制（13.6%）,恶心（9%）,乏力（9%）.结论 替吉奥维持治疗晚期乳腺癌效果肯定,不良反应轻微,耐受性良好,值得临床进一步推广、研究.Objective To observe the clinical efficacy and toxicity of S-1 as maintenance therapy in advanced breast cancer. Methods Retrospectively analysis 22 patients with advanced breast cancer who were received from January 2011 to April 2013. They were given S-1,40 - 60 mg （ 〈 1.25 m2,40 mg;1.25 - 1.5 m2 ,50 mg; 〉 1.5 m2 ,60 mg） ,twice/d,oral administration,d1 - d14,21 days was a cycle. Results Numbers of complete response, partial response, stable disease, progression disease of patients were 0,7,8and7 respective＊ ly. Of 22 patients,the RR was 31.8% ,the DCR was 68.1% ,the median PFS was 6. 8 months. The most fre- quent treatment-ralated adverse events were myelosuppression, nausea, lack of power. Conclusion S-1 as main- tenance treatment for advanced breast cancer is effective with minimal adverse reactions and can be tolerated by patients, so it is worthy of clinical promotion.

关 键 词：替吉奥 药物治疗 乳腺癌 疗效 

分 类 号：R737.9[医药卫生—肿瘤]